Dale Pcsolyar, MD
Neurology · Fredericksburg, VANPI 1104855485
Payments from drug & device makers
Across 149 payments — averaging $326.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$38K
- EMD Serono, Inc.$9K
- AbbVie$276
- Medtronic$226
- Genentech USA, Inc.$136
- UCB, Inc.$101
- plus $640 from 16 others
What the payments were for
- Consulting fees$10,70022%
- Speaking & faculty fees$31,79065%
- Travel & lodging$3,1176%
- Food & beverage$2,9886%
- Education$1090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 51 | $37,849 |
| EMD Serono, Inc. | 24 | $9,476 |
| AbbVie(2 entities) | 23 | $276 |
| Medtronic(2 entities) | 2 | $226 |
| Genentech USA, Inc. | 7 | $136 |
| UCB, Inc. | 5 | $101 |
| Novartis | 4 | $88 |
| Lilly USA, LLC | 4 | $69 |
| Supernus Pharmaceuticals, Inc. | 3 | $68 |
| Sunovion Pharmaceuticals Inc. | 8 | $67 |
| Teva Pharmaceuticals USA, Inc. | 3 | $63 |
| Sanofi | 3 | $60 |
| Amgen(2 entities) | 2 | $45 |
| Amneal Pharmaceuticals LLC | 2 | $32 |
| AstraZeneca | 1 | $31 |
| Acadia Pharmaceuticals Inc | 1 | $25 |
| TG Therapeutics, Inc. | 1 | $22 |
| Boston Scientific | 1 | $16 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
| Assertio Therapeutics, Inc. | 1 | $14 |
| Avion Pharmaceuticals | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$48,704 in reported general payments places this provider in the 80th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-LevodopaCarbidopa/Levodopa | 18 | $724 |
Paid to pharmacies, not to this prescriber.
Other neurology in Fredericksburg
- Michelle BetzVirginia Beach$3.3M
- Daniel CohenNorfolk$2.9M
- Heidi CraytonVienna$2.5M
- Ramsey FalconerAlexandria$2.4M
- Robert ShinCharlottesville$2.2M
- Simon FishmanAlexandria$1.6M
- Ingrid Loma MillerNorfolk$1.2M
- Matthew BarrettHenrico$1.1M
- James BickselMc Lean$1M
- Rahul DaveFairfax$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.